BAFNA PHARMACEUTICALS
|
The Current P/E Ratio of BAFNA PHARMACEUTICALS is 41.09.
Share Price | ₹74.5 | May 12,2025 |
Market Cap | ₹176.6 Cr | |
Earnings-TTM | ₹4.3 Cr | TTM-Standalone Results |
Price/Earnings | 41.09x | Calculated as Market Cap/Earnings |
---|---|---|
Explore Stock Analytics |
Definition & Calculation of PE (Price/Earnings) ratio of BAFNA PHARMACEUTICALS
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹176.6 Cr] as on May 12,2025
(/) Earnings [ ₹4.3 Cr] based on TTM-Standalone Results
(=) P/E Ratio [ 41.09x ]
Thus, for BAFNA PHARMACEUTICALS , the investors are currently willing to pay 41.09 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of BAFNA PHARMACEUTICALS !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of BAFNA PHARMACEUTICALS over the last five years.
Historical PE (Price/Earnings) ratio chart of BAFNA PHARMACEUTICALS
PE Ratio Performance Analysis for BAFNA PHARMACEUTICALS
- BAFNA PHARMACEUTICALS 's p/e ratio for fiscal years ending Mar2024 to Mar2020 averaged 31.05x.
- BAFNA PHARMACEUTICALS 's operated at median p/e ratio of 24.68x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, BAFNA PHARMACEUTICALS 's p/e ratio peaked in Mar2022 at 57.59x.
- BAFNA PHARMACEUTICALS 's p/e ratio hit its five-year low in Mar2020 of 0x.
How does BAFNA PHARMACEUTICALS 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
---|---|---|---|
BAFNA PHARMACEUTICALS | 4.30 | 41.09 | 176.6 |
SUN PHARMACEUTICAL INDUSTRIES LTD | 11,486.00 | 35.22 | 404,588.0 |
DIVIS LABORATORIES LTD | 2,067.00 | 76.30 | 157,711.0 |
CIPLA LTD | 5,000.43 | 24.42 | 122,115.0 |
TORRENT PHARMACEUTICALS LTD | 1,862.00 | 58.86 | 109,589.0 |
DR REDDYS LABORATORIES LTD | 5,703.50 | 17.49 | 99,746.6 |
MANKIND PHARMA LTD | 2,050.73 | 50.25 | 103,054.0 |
ZYDUS LIFESCIENCES LTD | 4,591.80 | 19.39 | 89,016.5 |
LUPIN LTD | 2,892.10 | 32.22 | 93,193.1 |
AUROBINDO PHARMA LTD | 3,500.25 | 20.01 | 70,044.7 |
ABBOTT INDIA LTD | 1,334.46 | 47.84 | 63,839.2 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs BAFNA PHARMACEUTICALS 's P/E Ratio
Top 10 Industry Peers | PE Ratio |
---|---|
Min industry PE | 17.49x |
Max industry PE | 76.30x |
Median industry PE | 35.22x |
Average industry PE | 38.46x |
You may also like the below Video Courses